Progen news from FierceBiotech
NewsProgen looks to M&A after late-stage failure
Australia's Progen says that it is focusing on M&A opportunities after deciding to shelve a Phase III study for its liver cancer therapy -- PI-88. The decision to halt the trial led to a rout of Read more...
ALSO NOTED: CFOs are pharma's new power players; Progen axes staff in restructuring; MethylGene inks collaboration deal;and muc
> Australia's Progen is laying off workers in a restructuring that includes outsourcing the commercial manufacture of PI-88. Read more...
| Press ReleasesPRESS RELEASE: US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer BRISBANE, Sept. 24 -- Progen Pharmaceuticals Limited announced today that its investigational anti-cancer drug PI-88 has Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets